Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 53Other hematologic neoplasm 25Plasma cell 11Myeloid 10Genitourinary 4Dermatologic 4Other neoplasm 3Thoracic 2Sarcoma 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2565Uterine Cervical Neoplasms 1684Endometrial Neoplasms 1008Fallopian Tube Neoplasms 729Carcinoma, Ovarian Epithelial 680Breast Neoplasms 673Neoplasms 436Carcinoma, Non-Small-Cell Lung 377Colorectal Neoplasms 370Pancreatic Neoplasms 302Stomach Neoplasms 301Uterine Cervical Dysplasia 273Prostatic Neoplasms 261Lung Neoplasms 250Melanoma 247Neoplasm Metastasis 214Peritoneal Neoplasms 197Carcinoma, Renal Cell 192Sarcoma 189Head and Neck Neoplasms 188Urinary Bladder Neoplasms 187Esophageal Neoplasms 186Recurrence 184Triple Negative Breast Neoplasms 179Uterine Neoplasms 176Vulvar Neoplasms 173Squamous Cell Carcinoma of Head and Neck 166Colonic Neoplasms 162Papillomavirus Infections 152Small Cell Lung Carcinoma 126

Interventions

enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immune System Diseases × Gynecologic × Clear all
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
GenitourinaryGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡